Q&A with Physician Researcher of the Year: Dr. Michael Fassett
Michael J. Fassett, MD, came to work at Kaiser Permanente in 2000. Since then, his dedication to his patients through research has grown. He’s published more than 50 research papers in peer-reviewed journals. Now, as the regional physician-in-charge for Maternal-Fetal Medicine and the area research ...
Featured News
Five questions for … Dr. Annette Langer-Gould
Annette Langer-Gould, MD, PhD, is a translational neuroscientist with the Southern California Permanente Medical Group. She treats people with multiple sclerosis (MS) at the Kaiser Permanente ...
COVID bivalent booster protects well against hospitalization
A Kaiser Permanente study shows the Pfizer-BioNTech BNT162b2 BA.4/5 bivalent mRNA vaccine helped protect against a range of COVID symptoms and was effective against the COVID XBB strain sublineages. ...
Kaiser Permanente Southern California to lead CDC-funded center to improve outbreak and disease prediction
Kaiser Permanente Southern California has been tapped to lead an innovation center that will develop advanced modeling approaches to better predict disease outbreaks and prepare the United States ...
Rates of heart failure deaths lower at Kaiser Permanente Southern California than U.S.
June 28, 2021A Kaiser Permanente Southern California research study found lower rates of heart failure mortality within the integrated health care system compared to the country as a whole. “In our study, we analyzed the overall rates of death attributable to heart failure throughout the state of California and United States, and then compared that to what we ...Read more...Kaiser Permanente Los Angeles Medical Center joins COVID-19 vaccine trial for children
June 11, 2021Kaiser Permanente Los Angeles Medical Center is participating in a clinical trial for the Moderna COVID-19 vaccine in children ages 6 months to less than 12 years. The KidCOVE study will evaluate the safety and efficacy of the Moderna COVID-19 vaccine (mRNA-1273), which is the same vaccine that was given Emergency Use Authorization (EUA) in December ...Read more...Kaiser Permanente Los Angeles Medical Center to study experimental stroke drug
June 4, 2021Kaiser Permanente Los Angeles Medical Center will conduct a multi-centered, randomized, Phase 3 research study to learn if the experimental drug recombinant Factor VIIa (rFVIIA), a protein that our body makes, can be used to decrease bleeding in the brain of patients who suffer sudden bleeding in the brain, also called intracerebral hemorrhage. The study entitled ...Read more...Marking Clinical Trials Day 2021 with gratitude
May 20, 2021On this day—May 20, 2021, aka Clinical Trials Day—we have more reasons than ever to celebrate the Kaiser Permanente Southern California clinical trials team. We began our COVID-19 clinical trials research with the remdesivir trial in March 2020. We were a top enroller in that study. Since then, our clinical trials program has participated in 9 ...Read more...Kaiser Permanente members have higher survival rate after cancer diagnosis
May 14, 2021Among insured cancer patients in Southern California, those who were diagnosed and treated at Kaiser Permanente, an integrated health care organization, had better survival rates, especially Black and Latinx patients, according to Kaiser Permanente research published in The American Journal of Managed Care. “Kaiser Permanente is committed to finding and addressing health care inequities,” said the ...Read more...COVID-19 outcomes are more severe for people of color
May 4, 2021A new Kaiser Permanente study published in Annals of Internal Medicine found that people of color were more likely to be hospitalized and to receive intensive-level care for COVID-19 compared to white patients even after adjusting for known health risk factors such as obesity, diabetes, and other conditions The study was among the first to show that these ...Read more...Celebrating our extraordinary nurses: During Nurses Week, all month, and throughout the year
May 4, 2021For National Nurses Week (May 6 to 12), Nurses Month, and Year of the Nurse, we celebrate the dedicated nurses who work in the Kaiser Permanente Southern California Department of Research & Evaluation. Nurses are a vital part of our research program. Most support clinical trials, where their relationship-building skills play an important part in helping ...Read more...5 questions for … Dr. Ana Florea
May 4, 2021Ana Florea, PhD, MPH, is an epidemiologist and post-doctoral research fellow with the Department of Research & Evaluation at Kaiser Permanente Southern California. She has special interests in vaccine safety and effectiveness, infectious diseases, cancer, and chronic kidney diseases. Currently, she is involved in projects studying shingles and Tdap vaccines. She works on projects involving ...Read more...New Kaiser Permanente COVID-19 Vaccine Side Effect Monitoring System launches
April 28, 2021A pilot program in Southern California will develop a vaccine side effect monitor that provides real-time insights to researchers and public health officials.Read more...Child vaccination rates recovering since pandemic’s early days
April 15, 2021The numbers of recommended vaccine doses, including measles vaccine, administered to children decreased dramatically after the declaration of a national state of emergency on March 13, 2020, due to the COVID-19 pandemic, according to a Kaiser Permanente study published in Pediatrics. While the decrease was lower and recovered in children under 2 years of age, ...Read more...